APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mirabegron Sustained-release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Mirabegron Sustained-release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchMirabegron Sustained-release Tablets Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Mirabegron Sustained-release Tablets Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Mirabegron Sustained-release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mirabegron Sustained-release Tablets Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Mirabegron Sustained-release Tablets Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Mirabegron Sustained-release Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Mirabegron Sustained-release Tablets include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mirabegron Sustained-release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mirabegron Sustained-release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mirabegron Sustained-release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mirabegron Sustained-release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Mirabegron Sustained-release Tablets Segment by Company

Alkem Laboratories

Astellas Pharma

Lupin Pharmaceuticals

Zydus Lifesciences

China Resources Pharmaceutical

Jiangsu Huayang Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

Qilu Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

CSPC Pharmaceutical

Sichuan Gowell Pharmaceutical

Zhejiang Huayi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Mirabegron Sustained-release Tablets Segment by Type

25mg per Tablet

50mg per Tablet

Mirabegron Sustained-release Tablets Segment by Application

Hospital and Clinic

Pharmacy

Other

Mirabegron Sustained-release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Sustained-release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Sustained-release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Sustained-release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mirabegron Sustained-release Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Mirabegron Sustained-release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Mirabegron Sustained-release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Mirabegron Sustained-release Tablets Industry Trends Table 2. Mirabegron Sustained-release Tablets Industry Drivers Table 3. Mirabegron Sustained-release Tablets Industry Opportunities and Challenges Table 4. Mirabegron Sustained-release Tablets Industry Restraints Table 5. Global Mirabegron Sustained-release Tablets Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Mirabegron Sustained-release Tablets Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Mirabegron Sustained-release Tablets Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Mirabegron Sustained-release Tablets Sales Market Share by Manufacturers Table 9. Global Mirabegron Sustained-release Tablets Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Mirabegron Sustained-release Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Mirabegron Sustained-release Tablets Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Mirabegron Sustained-release Tablets Manufacturers, Product Type & Application Table 13. Global Mirabegron Sustained-release Tablets Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Mirabegron Sustained-release Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 25mg per Tablet Table 17. Major Manufacturers of 50mg per Tablet Table 18. Global Mirabegron Sustained-release Tablets Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 20. Global Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 21. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026) Table 22. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2027-2032) Table 23. Global Mirabegron Sustained-release Tablets Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (K Units) Table 25. Global Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (K Units) Table 26. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2026) Table 27. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital and Clinic Table 29. Major Manufacturers of Pharmacy Table 30. Major Manufacturers of Other Table 31. Global Mirabegron Sustained-release Tablets Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 33. Global Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 34. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2026) Table 35. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2027-2032) Table 36. Global Mirabegron Sustained-release Tablets Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (K Units) Table 38. Global Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (K Units) Table 39. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2026) Table 40. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2027-2032) Table 41. Global Mirabegron Sustained-release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026) & (K Units) Table 43. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2021-2026) Table 44. Global Mirabegron Sustained-release Tablets Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Mirabegron Sustained-release Tablets Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 48. North America Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 49. Europe Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 51. Europe Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 58. Global Mirabegron Sustained-release Tablets Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Mirabegron Sustained-release Tablets Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Mirabegron Sustained-release Tablets Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2021-2026) Table 62. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2027-2032) Table 63. Alkem Laboratories Company Information Table 64. Alkem Laboratories Business Overview Table 65. Alkem Laboratories Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio Table 67. Alkem Laboratories Recent Development Table 68. Astellas Pharma Company Information Table 69. Astellas Pharma Business Overview Table 70. Astellas Pharma Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio Table 72. Astellas Pharma Recent Development Table 73. Lupin Pharmaceuticals Company Information Table 74. Lupin Pharmaceuticals Business Overview Table 75. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 77. Lupin Pharmaceuticals Recent Development Table 78. Zydus Lifesciences Company Information Table 79. Zydus Lifesciences Business Overview Table 80. Zydus Lifesciences Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio Table 82. Zydus Lifesciences Recent Development Table 83. China Resources Pharmaceutical Company Information Table 84. China Resources Pharmaceutical Business Overview Table 85. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 87. China Resources Pharmaceutical Recent Development Table 88. Jiangsu Huayang Pharmaceutical Company Information Table 89. Jiangsu Huayang Pharmaceutical Business Overview Table 90. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 92. Jiangsu Huayang Pharmaceutical Recent Development Table 93. Jiangxi Shanxiang Pharmaceutical Company Information Table 94. Jiangxi Shanxiang Pharmaceutical Business Overview Table 95. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 97. Jiangxi Shanxiang Pharmaceutical Recent Development Table 98. Qilu Pharmaceutical Company Information Table 99. Qilu Pharmaceutical Business Overview Table 100. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 102. Qilu Pharmaceutical Recent Development Table 103. Shenzhen Main Luck Pharmaceuticals Company Information Table 104. Shenzhen Main Luck Pharmaceuticals Business Overview Table 105. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 107. Shenzhen Main Luck Pharmaceuticals Recent Development Table 108. CSPC Pharmaceutical Company Information Table 109. CSPC Pharmaceutical Business Overview Table 110. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 112. CSPC Pharmaceutical Recent Development Table 113. Sichuan Gowell Pharmaceutical Company Information Table 114. Sichuan Gowell Pharmaceutical Business Overview Table 115. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 117. Sichuan Gowell Pharmaceutical Recent Development Table 118. Zhejiang Huayi Pharmaceutical Company Information Table 119. Zhejiang Huayi Pharmaceutical Business Overview Table 120. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 122. Zhejiang Huayi Pharmaceutical Recent Development Table 123. Chia Tai Tianqing Pharmaceutical Company Information Table 124. Chia Tai Tianqing Pharmaceutical Business Overview Table 125. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 127. Chia Tai Tianqing Pharmaceutical Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Mirabegron Sustained-release Tablets Distributors List Table 131. Mirabegron Sustained-release Tablets Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Mirabegron Sustained-release Tablets Product Image Figure 2. Global Mirabegron Sustained-release Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mirabegron Sustained-release Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Mirabegron Sustained-release Tablets Sales (2021-2032) & (K Units) Figure 5. Global Mirabegron Sustained-release Tablets Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Mirabegron Sustained-release Tablets Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 25mg per Tablet Image Figure 9. 50mg per Tablet Image Figure 10. Global Mirabegron Sustained-release Tablets Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Mirabegron Sustained-release Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2032) Figure 13. Global Mirabegron Sustained-release Tablets Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Mirabegron Sustained-release Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2032) Figure 16. Hospital and Clinic Image Figure 17. Pharmacy Image Figure 18. Other Image Figure 19. Global Mirabegron Sustained-release Tablets Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Mirabegron Sustained-release Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2032) Figure 22. Global Mirabegron Sustained-release Tablets Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Mirabegron Sustained-release Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2032) Figure 25. North America Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 27. U.S. Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 32. Germany Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 39. China Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 47. Brazil Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Mirabegron Sustained-release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Mirabegron Sustained-release Tablets Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Figure 58. North America Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Figure 60. Europe Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Mirabegron Sustained-release Tablets Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Mirabegron Sustained-release Tablets Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 25mg per Tablet
  • 50mg per Tablet
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Alkem Laboratories
  • Astellas Pharma
  • Lupin Pharmaceuticals
  • Zydus Lifesciences
  • China Resources Pharmaceutical
  • Jiangsu Huayang Pharmaceutical
  • Jiangxi Shanxiang Pharmaceutical
  • Qilu Pharmaceutical
  • Shenzhen Main Luck Pharmaceuticals
  • CSPC Pharmaceutical
  • Sichuan Gowell Pharmaceutical
  • Zhejiang Huayi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mirabegron Sustained-release Tablets Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mirabegron Sustained-release Tablets Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Mirabegron Sustained-release Tablets Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Mirabegron Sustained-release Tablets Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Mirabegron Sustained-release Tablets Market Dynamics
  1. 2.1 Mirabegron Sustained-release Tablets Industry Trends
  2. 2.2 Mirabegron Sustained-release Tablets Industry Drivers
  3. 2.3 Mirabegron Sustained-release Tablets Industry Opportunities and Challenges
  4. 2.4 Mirabegron Sustained-release Tablets Industry Restraints
3 Mirabegron Sustained-release Tablets Market by Manufacturers
  1. 3.1 Global Mirabegron Sustained-release Tablets Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Mirabegron Sustained-release Tablets Sales by Manufacturers (2021-2026)
  3. 3.3 Global Mirabegron Sustained-release Tablets Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Mirabegron Sustained-release Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Mirabegron Sustained-release Tablets Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Mirabegron Sustained-release Tablets Manufacturers, Product Type & Application
  7. 3.7 Global Mirabegron Sustained-release Tablets Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Mirabegron Sustained-release Tablets Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Mirabegron Sustained-release Tablets Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Mirabegron Sustained-release Tablets Tier 1, Tier 2, and Tier 3
4 Mirabegron Sustained-release Tablets Market by Type
  1. 4.1 Mirabegron Sustained-release Tablets Type Introduction
  2. 4.1.1 25mg per Tablet
  3. 4.1.2 50mg per Tablet
  4. 4.2 Global Mirabegron Sustained-release Tablets Sales by Type
  5. 4.2.1 Global Mirabegron Sustained-release Tablets Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mirabegron Sustained-release Tablets Sales by Type (2021-2032)
  7. 4.2.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2032)
  8. 4.3 Global Mirabegron Sustained-release Tablets Revenue by Type
  9. 4.3.1 Global Mirabegron Sustained-release Tablets Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Mirabegron Sustained-release Tablets Revenue by Type (2021-2032)
  11. 4.3.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2032)
5 Mirabegron Sustained-release Tablets Market by Application
  1. 5.1 Mirabegron Sustained-release Tablets Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Mirabegron Sustained-release Tablets Sales by Application
  6. 5.2.1 Global Mirabegron Sustained-release Tablets Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mirabegron Sustained-release Tablets Sales by Application (2021-2032)
  8. 5.2.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2032)
  9. 5.3 Global Mirabegron Sustained-release Tablets Revenue by Application
  10. 5.3.1 Global Mirabegron Sustained-release Tablets Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Mirabegron Sustained-release Tablets Revenue by Application (2021-2032)
  12. 5.3.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2032)
6 Global Mirabegron Sustained-release Tablets Sales by Region
  1. 6.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mirabegron Sustained-release Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026)
  4. 6.2.2 Global Mirabegron Sustained-release Tablets Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Mirabegron Sustained-release Tablets Revenue by Region
  1. 7.1 Global Mirabegron Sustained-release Tablets Revenue by Region
  2. 7.1.1 Global Mirabegron Sustained-release Tablets Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Mirabegron Sustained-release Tablets Revenue by Region (2021-2026)
  4. 7.1.3 Global Mirabegron Sustained-release Tablets Revenue by Region (2027-2032)
  5. 7.1.4 Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Mirabegron Sustained-release Tablets Revenue (2021-2032)
  8. 7.2.2 North America Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Mirabegron Sustained-release Tablets Revenue (2021-2032)
  11. 7.3.2 Europe Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Mirabegron Sustained-release Tablets Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Mirabegron Sustained-release Tablets Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Mirabegron Sustained-release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alkem Laboratories
  2. 8.1.1 Alkem Laboratories Company Information
  3. 8.1.2 Alkem Laboratories Business Overview
  4. 8.1.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio
  6. 8.1.5 Alkem Laboratories Recent Developments
  7. 8.2 Astellas Pharma
  8. 8.2.1 Astellas Pharma Company Information
  9. 8.2.2 Astellas Pharma Business Overview
  10. 8.2.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio
  12. 8.2.5 Astellas Pharma Recent Developments
  13. 8.3 Lupin Pharmaceuticals
  14. 8.3.1 Lupin Pharmaceuticals Company Information
  15. 8.3.2 Lupin Pharmaceuticals Business Overview
  16. 8.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  18. 8.3.5 Lupin Pharmaceuticals Recent Developments
  19. 8.4 Zydus Lifesciences
  20. 8.4.1 Zydus Lifesciences Company Information
  21. 8.4.2 Zydus Lifesciences Business Overview
  22. 8.4.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio
  24. 8.4.5 Zydus Lifesciences Recent Developments
  25. 8.5 China Resources Pharmaceutical
  26. 8.5.1 China Resources Pharmaceutical Company Information
  27. 8.5.2 China Resources Pharmaceutical Business Overview
  28. 8.5.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  30. 8.5.5 China Resources Pharmaceutical Recent Developments
  31. 8.6 Jiangsu Huayang Pharmaceutical
  32. 8.6.1 Jiangsu Huayang Pharmaceutical Company Information
  33. 8.6.2 Jiangsu Huayang Pharmaceutical Business Overview
  34. 8.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  36. 8.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
  37. 8.7 Jiangxi Shanxiang Pharmaceutical
  38. 8.7.1 Jiangxi Shanxiang Pharmaceutical Company Information
  39. 8.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
  40. 8.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  42. 8.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Shenzhen Main Luck Pharmaceuticals
  50. 8.9.1 Shenzhen Main Luck Pharmaceuticals Company Information
  51. 8.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  52. 8.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  54. 8.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  55. 8.10 CSPC Pharmaceutical
  56. 8.10.1 CSPC Pharmaceutical Company Information
  57. 8.10.2 CSPC Pharmaceutical Business Overview
  58. 8.10.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  60. 8.10.5 CSPC Pharmaceutical Recent Developments
  61. 8.11 Sichuan Gowell Pharmaceutical
  62. 8.11.1 Sichuan Gowell Pharmaceutical Company Information
  63. 8.11.2 Sichuan Gowell Pharmaceutical Business Overview
  64. 8.11.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  66. 8.11.5 Sichuan Gowell Pharmaceutical Recent Developments
  67. 8.12 Zhejiang Huayi Pharmaceutical
  68. 8.12.1 Zhejiang Huayi Pharmaceutical Company Information
  69. 8.12.2 Zhejiang Huayi Pharmaceutical Business Overview
  70. 8.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  72. 8.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
  73. 8.13 Chia Tai Tianqing Pharmaceutical
  74. 8.13.1 Chia Tai Tianqing Pharmaceutical Company Information
  75. 8.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
  76. 8.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  78. 8.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mirabegron Sustained-release Tablets Value Chain Analysis
  2. 9.1.1 Mirabegron Sustained-release Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mirabegron Sustained-release Tablets Production Mode & Process
  6. 9.2 Mirabegron Sustained-release Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mirabegron Sustained-release Tablets Distributors
  9. 9.2.3 Mirabegron Sustained-release Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst